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Bluetongue in 
Captive Yaks
To the Editor: In August 2006, 
several northern European countries 
including Belgium reported cases of 
bluetongue (BT) (1). This nonconta-
gious, arthropod-borne animal disease 
is caused by Bluetongue virus (BTV), 
genus  Orbivirus, family Reoviridae. 
The genome of BTV consists of 10 
segments of double-stranded RNA; 
24 serotypes have been reported (2). 
Serotype 8 (BTV-8) was implicated 
in the emergence in Belgium (3). All 
ruminant species are thought to be 
susceptible to BT (2). We report lab-
oratory-conﬁ  rmed clinical cases of BT 
in yaks (Bos grunniens grunniens).
Yaks living in captivity in a Bel-
gian animal park showed clinical signs 
of BT. A clinical examination per-
formed on 1 yak showed loss of weight 
associated with a progressive weak-
ness linked to anorexia, ulcerative and 
necrotic lesions on the muzzle with 
some crusts and mucopurulent nasal 
discharge, and udder erythema with 
papules and crusts. The tongue was se-
verely swollen and cyanotic and pro-
truded from the mouth (Figure). The 
animal was reluctant to move and was 
recumbent (possibly as a consequence 
of podal lesions linked to BT); it died 
7 days after examination. Necropsies 
were performed on carcasses of this 
and another yak. The main lesions 
found were severe diffuse congestion 
of the lungs with edema and emphy-
sema, acute hemorrhagic enteritis 
restricted to the ileum and jejunum, 
and petechial hemorrhages on the abo-
masums. No lesions characteristic of 
coronitis were noted.
Samples of spleen and bone 
marrow were taken and prepared ac-
cording to the method of Parsonson 
and McColl (4). A real-time reverse 
transcription quantitative–PCR (RT-
qPCR) targeting BTV segment 5 (RT-
qPCR_S5) was used to detect BTV 
RNA in tissues samples. Each test was 
performed in parallel with a RT-qPCR 
that ampliﬁ  es β-actin mRNA as an in-
ternal control (RT-qPCR_ACT). Both 
assays were conducted according to 
Toussaint and others (5), with slight 
modiﬁ  cations. Brieﬂ  y, total RNA was 
puriﬁ  ed from 25 mg of tissue by Trizol 
extraction (Invitrogen, Carlsbad, CA, 
USA) and denatured by heating for 3 
min at 95°C with 10% dimethylsul-
foxide (Sigma-Aldrich, St. Louis, MO, 
USA). Reverse transcription reactions 
were conducted by using the Taqman 
reverse transcription reagents accord-
ing to the manufacturer instructions 
(Applied Biosystems, Foster City, CA, 
USA). RT-qPCR reactions consisted 
of 1× concentrated Taqman fast uni-
versal PCR master mix (Applied Bio-
systems), 375 nM (β actin) or 500 nM 
(BTV) of each primer, 250 nM Taqman 
probe, and 5 μL cDNA. Cycling condi-
tions were as follows: 1 cycle at 95°C 
for 20 s, followed by 45 cycles of 1 s at 
95°C, and 20 s at 60°C. The speciﬁ  city 
of the RT-qPCR used had been previ-
ously tested against prototype strains 
of genetically related viruses (9 strains 
of epizootic hemorrhagic disease virus 
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Figure. A captive yak infected with bluetongue virus. Tongue is swollen, cyanotic, and 
protruding from the mouth.LETTERS
and 9 strains of African horse sickness 
virus) (5). The RT-qPCR tests con-
ﬁ  rmed BTV viremia.
The yak species in its natural 
biotope is usually rarely exposed to 
competent  Culicoides vectors. Anti-
bodies against BTV have been found 
in many wild ruminants (6), and our 
results extend the number of ruminant 
species susceptible to BTV. In the 
northern European BT outbreak, le-
sions in cattle and sheep were mainly 
localized to the regions of the muzzle, 
mouth, and eye; clinical signs were 
not always obvious (7,8). As in cattle 
and sheep, clinical signs in yaks were 
observed on the muzzle, in the perio-
cular region, and around and inside 
the mouth. These signs clearly reﬂ  ect-
ed viral-induced endothelial damage 
triggering disseminated intravascular 
coagulation and a hemorrhagic diath-
esis commonly described in sheep and 
cattle (2). In our case, lesions depicted 
pronounced microvascular damage. 
According to the severity of the le-
sions and rates of illness and death ob-
served, the yak, like sheep, appears to 
be highly susceptible to BTV.
In the epidemiology of BT in Afri-
can countries, cattle and wild ruminant 
species such as antelopes play a role 
as asymptomatic reservoir hosts of the 
virus (2). Some wild ruminant species 
in captivity could also play this role 
in European countries affected by the 
recent BT outbreak. These cases could 
be of particular concern for all parks 
and zoos that gather numerous wild 
ruminants. Illness, reproductive fail-
ure, and deaths usually reported with 
BT (9) could generate substantial loss-
es on these premises. Moreover, the 
source of BTV-8 in the northern Eu-
ropean outbreak remains unclear, and 
the role of wild ruminant species has 
to be taken into account. In the future, 
European authorities should consider 
vaccination to prevent the spread of 
the disease in European member states 
(10). All premises with wild ruminants 
need to be involved in BT control and 
prophylaxis.
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Murine Typhus, 
Algeria
To the Editor: Rickettsioses, or 
typhoid diseases, are caused by obli-
gate intracellular bacteria of the order 
Rickettsiales. The ubiquitous murine 
typhus is caused by Rickettsia typhi. 
Although cat ﬂ  eas and opposums have 
been suggested as vectors in some 
places in the United States, the main 
vector of murine typhus is the rat ﬂ  ea 
(Xenopspylla cheopis), which main-
tains R. typhi in rodent reservoirs (1). 
Most persons become infected when 
ﬂ   ea feces containing R. typhi con-
taminate broken skin or are inhaled, 
although infections may also result 
from ﬂ  ea bites (1). Murine typhus is 
often unrecognized in Africa; how-
ever, from northern Africa, 7 cases in 
Tunisia were documented in 2005 (2).
We conducted a prospective 
studyin Algeria which included all 
patients who had clinical signs lead-
ing to suspicion of rickettsioses (high 
fever, skin rash, headache, myalgia, 
arthralgia, eschar, or reported contact 
with ticks, ﬂ  eas, or lice) who visited 
the Oran Teaching Hospital in 2004–
2005 for an infectious diseases con-
sultation. Clinical and epidemiologic 
data as well as acute-phase (day of 
admission) and convalescent-phase 
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